onthedarkside Posted May 26, 2023 Share Posted May 26, 2023 Earlier this year, U.S. regulators settled on a new strategy for COVID-19 vaccines. Like the annual flu shot, the vaccines will be updated each year based on the virus’ evolution, then rolled out in the fall. Accordingly, on 15 June, advisers to the U.S. Food and Drug Administration will weigh which strain or strains of SARS-CoV-2 should make up the next iteration of vaccine, so that the agency can greenlight a version for companies to mass-produce. READ MORE https://www.science.org/content/article/covid-19-vaccines-may-undergo-major-overhaul-fall 1 Link to comment Share on other sites More sharing options...
TorquayFan Posted May 27, 2023 Share Posted May 27, 2023 (edited) Darkside - lets hope by the time this vax is widely administered, the variants in the vax are still relevant to the variant ruling in the community . . . My other reservation is about vax in mRNA format - after side effects after my 4th it's a NO from me ! I'm hopeful that a daily dose of 5000iu vitamin D3 will help ward off another bout of Covid for me. We need better vax than there have been so far - something better - a 2nd Generation. This is one of many such projects : https://www.scancell.co.uk/a-novel-bivalent-dna-vaccine-encoding-both-spike-protein-receptor-binding-domain-and-nucleocapsid-protein-of-sars-cov-2-to-elicit-t-cell-and-neutralising-antibody-responses-that-cross-react-with-variants-1 I'm hoping for a better alternative to arise. Edited May 27, 2023 by TorquayFan 1 Link to comment Share on other sites More sharing options...
TorquayFan Posted May 30, 2023 Share Posted May 30, 2023 Darkside - more about this DNA vax today - "Abstract - Although the efficacy of vaccines targeting SARS-CoV-2 is apparent nowthat the approved mRNA and adenovirus vector vaccines are in widespreaduse, the longevity of the protective immune response and its efficacyagainst emerging variants remains to be determined. We have thereforedesigned a DNA vaccine encoding both the SARS-CoV-2 spike receptor-binding domain (‘RBD’) and nucleocapsid proteins, the latter of which ishighly conserved amongst beta coronaviruses. The vaccine elicits strongpro-inflammatory CD4+ Th1 and CD8+ T-cell responses to both proteinsin mice and rats, with responses being significantly enhanced by fusingthe nucleocapsid sequence to a modified Fc domain. We have shown thatthe vaccine also stimulates high titre antibody responses to RBD in micethat efficiently neutralise in pseudotype and live virus neutralisation assaysand show cross reactivity with spike proteins from the variants B.1.1.7(Alpha), B.1.351 (Beta) and B.1.617.2 (Delta). The vaccine also showedgood protection in a viral challenge model in ACE2 receptor transgenicmice. This DNA platform can be easily adapted to target variant proteinsand we show that a vaccine variant encoding the Beta variant sequencestimulates cross-reactive humoral and T cell responses. These data supportthe translation of this DNA vaccine platform into the clinic, therebyoffering a particular advantage for rapidly targeting emerging SARS-CoV-2 variants." https://www.scancell.co.uk/Data/Sites/1/media/publications/papers/brentville-et-al-2023.pdf Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now